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Abstract
Klebsiella pneumoniae strains co-producing klebsiella pneumoniae
carbapenemase (KPC) and verona integron-encoded metallo-beta-
lactamase (VIM) are frequently isolated in Greece and have also
occurred in other European countries. Conventional combined
disc tests exhibit low sensitivity against these emerging pathogens.
We have evaluated modiﬁcations of the KPC/Metallo-b-Lactamase
Conﬁrmation kit (ROSCO) exhibiting high diagnostic value against
KPC, VIM and KPC + VIM producers. The key changes were the
inclusion of additional combined tablets containing meropenem
plus two inhibitors (dipicolinic acid (1000 lg per tablet) for
metallo-b-lactamases and a boronic acid derivative for KPCs) and
the replacement of aminophenylboronic acid by phenylboronic
acid (400 lg per tablet).
Keywords: Carbapenemase, combined disc test, Klebsiella
pneumoniae, KPC, VIM
Original Submission: 27 December 2012; Revised
Submission: 30 March 2013; Accepted: 31 March 2013
Editor: R. Canton
Article published online: 5 April 2013
Clin Microbiol Infect 2013; 19: E412–E415
10.1111/1469-0691.12238
Corresponding author: V. Miriagou, Laboratory of Bacteriology,
Hellenic Pasteur Institute, Vas. Soﬁas Ave. 127, 11521 Athens, Greece
E-mail: miriagou@pasteur.gr
Routine detection of carbapenemase-producing Klebsiella pneu-
moniae and other enterobacteria in the clinical laboratory is
not included in the latest recommendations of CLSI [1] and
EUCAST (www.eucast.org/clinical_breakpoints/). Neverthe-
less, application of reliable detection methods is essential in
surveys performed to delineate the epidemiology of these
pathogens and to control their spread [2,3]. There are various
carbapenemase-detecting methods grouped as phenotypic
[based on the synergy between carbapenems and inhibitors
of metallo-b-lactamases (MbLs), e.g. EDTA and dipicolinic acid,
as well as boronates active against klebsiella pneumoniae
carbapenemases (KPCs)], molecular (mainly PCR-based
assays), and biochemical (e.g. determination of imipenem
hydrolysis) [3,4].
Combined disc synergy tests have been extensively used
because of their convenience and low cost. However, changes
in carbapenemase-producing bacterial populations may com-
promise the performance of these assays. Previous studies
have documented the spread of K. pneumoniae strains co-
producing KPC and verona integron-encoded metallo-beta-
lactamase (VIM) b-lactamases in Greek hospitals [5–8]. It has
been estimated that the double carbapenemase producers
(DCPs) in this setting comprise approximately 5.5% of all
carbapenemase-positive K. pneumoniae isolates [9]. Also, hos-
pital infections caused by K. pneumoniae co-producing KPC and
VIM or IMP b-lactamases have been described in Germany,
Italy, China and Colombia [10–14]. Double carbapenemase
producers may ‘deceive’ the conventional combined disc tests,
frequently appearing negative for one or even both carbapen-
emases [5,6,12].
We report here on two modiﬁcations (Methods A and B) of
the KPC/MbL kit (ROSCO Diagnostica, Taastrup, Denmark)
aiming to increase the reliability of DCP detection. The latter
kit includes four tablets: meropenem (10 lg), meropenem +
aminophenylboronic acid (600 lg), meropenem + dipicolinic
acid (1000 lg) and meropenem + cloxacillin (750 lg) (www.
rosco.dk) [15,16]. In Method A, an additional tablet containing
meropenem + aminophenylboronic acid + dipicolinic acid was
included. Method B differed from Method A only in that
phenylboronic acid (400 lg) was used instead of amin-
ophenylboronic acid. Performance of Methods A and B was
compared with that of the original KPC/MbL kit, as well as a
recently described assay using four discs: meropenem, me-
ropenem + phenylboronic acid, meropenem + EDTA and
meropenem + phenylboronic acid + EDTA (Method C) [17].
Methods were tested against a challenge set of 125
K. pneumoniae isolates from the collection of the Hellenic
Pasteur Institute. Isolates had been characterized as described
previously [5,6,18]. The set included 26 KPC-positive, 35 VIM-
positive and 40 isolates positive for both VIM and KPC
enzymes. The remaining isolates were OXA-48 plus extended
spectrum b-lactamase (n = 5) and extended spectrum
b-lactamase and/or AmpC producers (n = 19) (Table 1). The
range of imipenem and meropenem MICs for VIM and/or KPC
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carbapenemase-producing isolates as well as for the OXA-48-
positive isolates was from 1 to >32 mg/L. The MIC50 and
MIC90 values for both carbapenems were 32 and >32 mg/L,
respectively. The respective values for carbapenemase-
negative isolates (extended spectrum b-lactamase and/or
AmpC producers) were signiﬁcantly lower (MIC ranges for
imipenem and meropenem were 1–2 and 0.5–8 mg/L, respec-
tively). Twenty-one (80.89%) of the KPC producers were
classiﬁed into sequence type 258 and the remaining were
scattered into sequence types 133 (n = 2) and 383 (n = 3).
The VIM-positive isolates as well as DCPs were distributed
into sequence types 147 (n = 56, 22 DCPs), 323 (n = 5, 5
DCPs), 383 (n = 12, 12 DCPs) and 945 (n = 2, 1 DCP).
The algorithm used to interpret results obtained by Methods
A and B is described in Fig. 1. An isolate was classiﬁed as KPC-
positive when aminophenylboronic acid or phenylboronic acid
caused a >4 mm increase in the inhibitory zone diameter of
meropenem. A difference of >5 mm between the inhibitory
zone diameters around discs containing meropenem + dipicol-
inic acid and meropenem alone indicated MbL production. To
facilitate detection of DCPs, inhibition by the meropenem +
dipicolinic acid + aminophenylboronic acid/phenylboronic acid
discs was considered for all isolates appearing positive for either
carbapenemase type or negative for both. Hence, a >4-mm
difference in inhibition zone by the ‘triple’ disc compared with
meropenem + dipicolinic acid was regarded as indicative of KPC
production. Also, a similar inhibition zone difference between
the ‘triple’ and meropenem + aminophenylboronic acid/phen-
ylboronic acid discs indicated MbL production. In cases of
negative results with both ‘double’ discs as well as the ‘triple’
disc, other carbapenem-resistance mechanisms, most impor-
tantly ΟΧΑ-48 production, must be considered.
Results are summarized in Table 1. The KPC/MbL kit, as well
as Methods A, B and C exhibited excellent speciﬁcity; false
positives among the isolates lacking either VIM or KPC
carbapenemases and possessing AmpC and/or extended spec-
trum b-lactamase producers) were not observed. However,
one out of the ﬁve OXA-48-positive isolates was falsely
classiﬁed as an MbL producer. Also, all four methods performed
well against the 61 single carbapenemase producers. The KPC/
MbL kit and Method A failed to detect carbapenemase in three
KPC producers whereas Method B correctly classiﬁed all but
one single carbapenemase producer. Method C misclassiﬁed a
KPC-positive isolate as a producer of both carbapenemase
TABLE 1. Performance of combined disc methods for detection of KPC-producing and/or VIM-producing Klebsiella pneumoniae
b-Lactamase content
(No. of isolates)
KPC/Metallo-b-lactamase
kit
Modiﬁcations of KPC/Metallo-b-lactamase kit
Method A Method B Method C
Correctly
classiﬁed Misclassiﬁed
Correctly
classiﬁed Misclassiﬁed
Correctly
classiﬁed Misclassiﬁed
Correctly
classiﬁed Misclassiﬁed
KPC-2(4) 3 1 3 1 4 0 3 1
KPC-2 plus AmpC and/or ESBL(22) 20 2 20 2 21 1 22 0
VIM-1 (20) 20 0 20 0 20 0 20 0
VIM-1 plus AmpC and/or ESBL(15) 15 0 15 0 15 0 15 0
KPC-2 + VIM-1(15) 3 12 5 10 14 1 7 8
KPC-2 + VIM-1 plus AmpC
and/or ESBL(25)
5 20 17 8 25 0 19 6
OXA-48 + ESBL(5) 4 1 4 1 4 1 4 1
AmpC and/or ESBL(19) 19 0 19 0 19 0 19 0
Total(125) 89 36 103 22 122 3 109 16
ESBL, extended spectrum b-lactamase
Screening 
Imipenem MIC ≥1 
or  
Meropenem MIC ≥0.5   
Synergy of MEM with APBA/PBA
(≥4mm) 
Synergy of MEM with DPA  
(≥5mm) 
KPC  AmpC  
Synergy with  
cloxacillin 
(≥5mm) 
Synergy with MEM+DPA+APBA/PBA 
(double inhibitor) 
KPC+MBL 
No synergy with  
cloxacillin 
(<5mm) 
Increase of double inhibitor 
zone against 
APBA/PBA ≥4mm AND 
DPA ≥4mm  
KPC  
Increase of double inhibitor  
zone against  
DPA zone ≥ 4mm  
Increase of double inhibitor
zone against
APBA/PBA zone ≥ 4mm
MBL MBL
FIG. 1. Algorithm used for interpretation of results obtained by the KPC/Metallo-b-Lactamase Conﬁrmation-based Methods A and B that included
an additional double inhibitor disc.
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types. Signiﬁcant problems, however, were encountered with
the subset of the 40 DCPs. The lowest sensitivity was observed
with the KPC/MbL kit, which missed 32 DCPs. Method A
displayed low sensitivity—detecting production of both carba-
penemase types in only 22 of these isolates. Sensitivity was
dramatically improved by replacing aminophenylboronic acid
with phenylboronic acid. Indeed, Method B correctly classiﬁed
39 DCPs. Most of the DCPs misclassiﬁed by the above assays
appeared as MbL producers. The performance of MethodCwas
comparable with that of Method A.
It has been shown previously that phenylboronic acid is
more effective than aminophenylboronic acid in detecting KPC
producers by boronate-based combined disc assays [19].
Hence, the better diagnostic value of Method B over Method A
against DCPs can be attributed to the use of phenylboronic
acid instead of aminophenylboronic acid. Apparently, phen-
ylboronic acid reduced the masking effect of the simulta-
neously produced VIM more efﬁciently than
aminophenylboronic acid. We did not systematically pursue
the sources of DCP classiﬁcation errors of Method C.
Speciﬁcity problems caused by EDTA, as reported previously
[15], were not observed, probably because relatively low
amounts of the inhibitor were used [17]. Yet, the proposed
algorithm in Method C implies a questionable term that may
partly explain DCP misclassiﬁcations: results of the merope-
nem + phenylboronic acid + EDTA-containing discs were
taken into account only in K. pneumoniae isolates that were
found to be negative for both carbapenemase types by the
respective meropenem + single inhibitor discs [17]. Appar-
ently, in Method C, the fact that a DCP may appear as a single
carbapenemase producer was overlooked.
The main limitation of this study is that it includes isolates
from a single enterobacterial species, K. pneumoniae, carrying
only two carbapenemase types, KPC and VIM. Yet, the
proposed modiﬁcation (Method B) of the KPC/MbL kit
resulted in a clear improvement in detection of the emerging
group of double carabapenemase-producing K. pneumoniae.
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